Comparative Pharmacology
Head-to-head clinical analysis: AVC versus SULFALOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVC versus SULFALOID.
AVC vs SULFALOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVC (sulfanilamide) is a sulfonamide antibiotic that inhibits bacterial dihydrofolate synthesis by competing with para-aminobenzoic acid (PABA), thereby blocking folic acid production and bacterial growth.
Sulfaloid is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production in susceptible bacteria.
1 applicatorful (approximately 5 g of 0.1% cream) intravaginally once daily at bedtime for 7 days.
500 mg orally every 12 hours for 7-10 days.
None Documented
None Documented
3-5 hours; prolonged in renal impairment (up to 12 hours).
Terminal elimination half-life: 6-8 hours in adults with normal renal function (ClCr >90 mL/min); prolonged to 12-20 hours in moderate renal impairment (ClCr 30-50 mL/min) and >30 hours in severe renal impairment (ClCr <30 mL/min).
Renal: 30-50% unchanged; biliary/fecal: 10-20% as metabolites.
Renal: 70% (unchanged via glomerular filtration and tubular secretion); Biliary/fecal: 20% (conjugated metabolites); 10% metabolized in liver to inactive acetylated derivatives.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)